A serial study of new MS lesions and the white matter from which they arise

Neurology

Volumn 51, Issue 6, 1998, Pages 1689-1697

  Goodkin, D E ^a,b,c,d,e   Rooney, W D ^a   Sloan, R ^b   Bacchetti, P ^c   Gee, L ^d   Vermathen, M ^d   Waubant, E ^c   Abundo, M ^b   Majumdar, S ^a   Nelson, S ^c   Weiner, M W ^b  

^a Departments of Neurology   (United States)

^b Department of Radiology ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; TISSUE INJURY; WHITE MATTER;

EID: 0031672541     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.6.1689     Document Type: Article

References (39)

1. Grossman RI. Magnetic resonance imaging: current status and strategies for improving MS clinical trial design. In: Goodkin DE, Rudick RA, eds. Multiple sclerosis: advances in clinical trial design, treatment and future perspectives. London: Springer-Verlag, 1996:161-186.
2. Filippi M, Campi A, Martinelli V, et al. Transitional progressive multiple sclerosis: MRI and MTI findings. Acta Neurol Scand 1995;92:178-182.
3. van Buchem MA, McGowan JC, Kolson DL, Polansky M, Grossman RI. Quantitative volumetric magnetization transfer analysis in multiple sclerosis: estimation of macroscopic and microscopic disease burden. Magn Reson Med 1996;36:632636.
4. Horsfield MA, Lai M, Wegg SL, et al. Apparent diffusion coefficients in benign and secondary progressive multiple sclerosis by nuclear magnetic resonance. Magn Reson Med 1996;36: 393-400.
5. Christiansen P, Gideon P, Thomsen C. Stuggaard M, Henriksen O, Larsson HBW. Increased water self-diffusion in chronic plaques and in apparently normal white matter in patients with multiple, sclerosis. Acta Neurol Scand 1993;87:195-199.
6. Roser W, Hagberg G, Mader I, et al. Proton MRS of gadolinium-enhancing MS plaques and metabolic changes in normal appearing white matter. Magn Reson Med 1995;33: 811-817.
7. Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41:385-391.
8. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990;14:154-159.
9. Rooney WD, Goodkin DE, Schuff N, et al. 'H MRSI of normal appearing white matter in multiple sclerosis. Multiple Sclerosis 1997;3:231-237.
10. Alien IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979;41:81-91.
11. Powell HC, Lanpert PW. Pathology of multiple sclerosis. Neurol Clin 1983; 1:631-644.
12. van Buchem MA, McGowan JC, Kolson DL, Polansky M, Grossman RI. Quantitative volumetric magnetization transfer analysis in multiple sclerosis: estimation of macroscopic and microscopic disease burden. Magn Reson Med 1996;36:632636.
13. Lai HM, Davie ÇA, Gass A, et al. Serial magnitisation transfer ratios in gadolinium-enhancing lesions in multiple sclerosis. J Neurol 1997;244:308-311.
14. Brainin M, Neuhold A, Reisner T, Maida E, Lang S, Deecke L. Changes within the "normal" cerebral white matter of multiple sclerosis patients during acute attacks and during highdose cortisone therapy assessed by means of quantitative MRI. J Neurol Neurosurg Psychiatry 1989;52:1355-1359.
15. Goodkin DE, Rooney W, et al. PD, Tl, gadolinium (Gd+) intensities, T2 and MTRs are chronically diffusely abnormal in MS brain and on monthly MRI scans are related to the appearance of new Gd+ lesions in normal appearing white matter (NAWM). Neurology 1998;50:A191. Abstract.
16. Filippi M, Rocca MA, Martino G, Horsfield MA, Como G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998;43:809-814.
17. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
18. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 1983;33: 1444-1452.
20. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole-peg tests. Arch Phys Med Rehabil 1988;69:850-854.
21. Barkhof F, Tas MW, Frequin STFM, et al. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994;36:382-387.
22. Woods RP, Mazziotta JC, Cherry SR. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 1992;16:620-633.
23. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993;17: 536-546.
24. Whitall KP, MacKay AL, Graeb DA, Nugent RA, Li DKB, Paty D. In vivo measurement of T2 distributions and water content in normal human brain. Magn Reson Med 1997;37: 34-43.
25. Morrissey SP, Stodal H, Zettl U, et al. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis: quantification of inflammation and oedema. Brain 1996;119:239-248.
26. Newcombe J, Hawkins CP, Henderson CL, et al. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain 1991;114:1013-1023.
27. Barnes D, Munro PMG, Youl BD, et al. The longstanding MS lesions. A quantitative MRI and electron microscopic study. Brain 1991;114:1271-1280.
28. Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42:783-793.
29. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bö L. Axonal transaction in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
30. McFarland HF, Frank JA, Albert PS, et al. Using gadoliniumenhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758766.
31. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994;36:S25-S28.
32. Mohr DC, Russo D, Reiss M, Chang J, Goodkin DE. Relationship of stress, psychological distress, and disease activity in multiple sclerosis patients. Ann Neurol 1997;42:443. Abstract.
33. Franklin GM, Nelson LM, Heaton RK, Burks JS, Thompson DS. Stress and its relationships to acute exacerbation in multiple sclerosis. J Neurol Rehabil 1988;2:398-403.
34. Sharief MK, Hentges R. Association between TNF alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-472.
35. Sharief MK, Thompson EJ. Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993;56:169-174.
36. Martino G, Filippi M, Martinelli V, et al. Interferon-gamma induced increases in intracellular calcium in T lymphocytes from patients with multiple sclerosis precede clinical exacerbations and detection of active lesions on MRI. J Neurol Neurosurg Psychiatry 1997;63:339-345.
37. Trojano M, Avolio C, Simone IL, et al. Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings. Neurology 1996;47:15351541.
38. Anthony DC, Ferguson B, Matysak MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 1997;23:406-415.
39. Wolansky LJ, Bardini JA, Cook SD, Zimmer AE, Sheffet A, Lee HJ. Triple-dose versus single-dose gadoteridol in multiple sclerosis patients. J Neuroimag 1994;4:141-145.